Objectives: A series of randomized controlled trials have shown the efficacy of glabellar
botulinum toxin (BTX) injection as a treatment for depression in women. We wanted to …

Background Due to individual differences and lack of objective biomarkers, only 30-40%
patients with major depressive disorder (MDD) achieve remission after initial antidepressant …

BackgroundVortioxetine has demonstrated dose-dependent efficacy in patients with major
depressive disorder (MDD), with the greatest effect observed with vortioxetine 20 mg/day …

Background Prior studies have demonstrated that early treatment response with transcranial
magnetic stimulation (TMS) can predict overall response, yet none have directly compared …

Objective The objective of this evidence-based structured review was to determine if there is
consistent evidence that pain interferes with achieving antidepressant treatment …

Although the currently available antidepressants are well established in the treatment of the
major depressive disorder (MDD), there is strong variability in the response of individual …

The aim of this study is to identify the difference of temporal variability among major
depressive disorder (MDD) patients (with different early antidepressant responses) and …

Background Despite the widespread use of antidepressants in clinical practice, the current
trial-and-error approach to medication selection contributes to treatment failure and …

Objective To identify actionable predictors of remission to antidepressant pharmacotherapy
in depressed older adults and to use signal detection theory to develop decision trees to …

The aim of this study was to test whether early symptom improvement predicts final response
and remission for patients with major depressive disorder (MDD) receiving electroconvulsive …